Summit Therapeutics Inc. (SMMT) Stock Score, Valuation & Financial Research

Summit Therapeutics Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for SMMT

Summit Therapeutics Inc. does not currently have a complete Wall Street Score. The stored market price is USD 17.34. These figures are a research snapshot, not a buy or sell recommendation.

What Summit Therapeutics Inc. does

Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Summit Therapeutics is a biopharmaceutical company that generates value through the research, development, and potential commercialization of oncology-focused medicinal therapies. The company currently operates as a clinical-stage entity, relying on capital raises and strategic licensing agreements to fund its pipeline rather than recurring product sales.

Products and services

  • The company's primary product candidate is ivonescimab, a novel PD-1/VEGF-A bispecific antibody licensed from Akeso for development and commercialization in specific territories.

Customer types

Healthcare providers and patients.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on unnamed third-party contract manufacturing organizations for the production of clinical trial materials. Source

Business relationships and partnerships

  • Akeso, Inc. — A strategic licensing agreement under which Summit obtained rights to develop and commercialize ivonescimab in the United States, Canada, Europe, Japan, Latin America, and other territories. Source

Competitors and product-market comparisons

  • Biopharmaceutical companies in oncology — The company competes with various established pharmaceutical and biotechnology companies developing PD-1 or VEGF-targeted therapies for oncology indications. Source

Business strengths to evaluate

  • Clinical pipeline focused on bispecific antibody technology Source

Business risks and research considerations

  • Dependence on third-party licensors and contract manufacturers Source
  • Clinical trial failure and regulatory approval uncertainty Source
  • Currency exchange rate volatility Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

SMMT financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 17.34
Market capitalization:
13.83B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -856.09M
Free cash flow:
USD -240.15M
Cash:
USD 419.37M
Total debt:
USD 20.38M
EPS:
USD -1.12

What stands out

  • Free cash flow is USD -240.15M, negative for the stored period.
  • The balance sheet shows USD 419.37M of cash versus USD 20.38M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 398.98M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for SMMT

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can SMMT fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is SMMT likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for SMMT to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of SMMT's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research SMMT

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.